Associated tags: Microscopy, Life, Proteomics, Cell biology, Research, Health, Science, Other Science, Medical Supplies, CER, Culture, Project, EPS, Corporation, Spiral Dynamics, Operational excellence, BRKR
Locations: SPAIN, AST, UNITED STATES, NORTH AMERICA, MASSACHUSETTS, NEW YORK, FLORIDA, ITALY, EUROPE, WASHINGTON, GERMANY, LUXEMBOURG, CALIFORNIA, CI
Engineering,
Technology,
Manufacturing,
Other Science,
Research,
Science,
Hardware,
Food,
LC-MS,
Bruker,
Multimedia,
GC-MS,
Chromatography,
Plasma protein binding,
GC,
ASMS,
Chemical ionization,
Water,
Record,
LC-MS/MS,
EI,
NIST,
Natural rubber The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024:
Key Points:
- The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024:
This press release features multimedia.
- With a 20-second analysis time per sample, it provides a fast solution for routine food and environmental testing.
- Jeffrey Zonderman, President of the Bruker Applied Mass Spectrometry division, commented: “With the world’s first fully integrated DART-TQ-MS system, we are pioneering chromatography-free workflows for the applied markets and for point-of-need mass spec applications.
- Like I said, these Bruker DARTs could be game-changers.”
Bruker Applied Mass Spectrometry also launches the ecTOF™ , a novel, compact time-of-flight mass spectrometer for high-resolution GC-HRMS that records EI and CI spectral data in a single GC run.
Research,
Technology,
Semiconductor,
Genetics,
Nanotechnology,
Biotechnology,
Pharmaceutical,
Health,
Science,
Artificial Intelligence,
Corporation,
Conference,
BRKR,
Bruker Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:
Key Points:
- Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:
2024 Jefferies Global Healthcare Conference, New York, NY
45th Annual Goldman Sachs Global Healthcare Conference, Miami, FL
Live audio webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com .
- Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for at least 30 days following the presentations.
Biotechnology,
Manufacturing,
Other Health,
Health,
Pharmaceutical,
Health Technology,
Other Science,
Medical Devices,
Research,
Engineering,
Science,
Bruker,
Security (finance),
BofA Securities,
J. P. Morgan,
Form S-3,
Corporation,
Sale,
Form,
Prospectus,
Attention,
BRKR,
Broadridge Financial Solutions Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock.
Key Points:
- Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock.
- Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock.
- The offering is expected to close on or about May 31, 2024, subject to market and other customary closing conditions.
- BofA Securities and J.P. Morgan are acting as joint underwriters and book-running managers for the offering.
Biotechnology,
Manufacturing,
Other Health,
Health,
Pharmaceutical,
Other Science,
Medical Devices,
Research,
Other Manufacturing,
Engineering,
Science,
Bruker,
Security (finance),
BofA Securities,
J. P. Morgan,
Form S-3,
Corporation,
Sale,
Form,
Prospectus,
Attention,
BRKR,
Broadridge Financial Solutions Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock.
Key Points:
- Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock.
- In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock.
- The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- The offering will be made only by means of a prospectus forming a part of that effective registration statement.
Research,
Technology,
Semiconductor,
Genetics,
Nanotechnology,
Biotechnology,
Pharmaceutical,
Health,
Science,
Artificial Intelligence,
Bruker,
Corporation,
Q&A,
Event,
EDT Bruker also expects to provide an update to its medium-term financial outlook.
Key Points:
- Bruker also expects to provide an update to its medium-term financial outlook.
- The Investor Webinar will include presentations by CEO Frank H. Laukien, CFO Gerald Herman, and by the leaders of these three new Bruker businesses, Bernd Gleixner, Christoph Gauer and Mark Munch.
- The link to the Investor Webinar and dial-in option info will be available in the Events & Presentations section of the Company’s Investor Relations website at https://ir.bruker.com .
- A replay will be available on Bruker’s Investor Relations website after the conclusion of the event.
Research,
Technology,
Semiconductor,
Genetics,
Nanotechnology,
Biotechnology,
Pharmaceutical,
Health,
Science,
Artificial Intelligence,
Corporation,
BRKR,
Bruker Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on June 17, 2024 to stockholders of record as of June 3, 2024.
Key Points:
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on June 17, 2024 to stockholders of record as of June 3, 2024.
Research,
Technology,
Genetics,
Nanotechnology,
Biotechnology,
Pharmaceutical,
Health,
Science,
Artificial Intelligence,
Other Science,
BRKR,
Bruker,
EDT,
Corporation,
Event,
Q&A Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business.
Key Points:
- Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business.
- Bruker also expects to provide an update to its medium-term financial outlook.
- The Investor Webinar will include presentations by CEO Frank H. Laukien, CFO Gerald Herman, and by the leaders of these three new Bruker businesses, all followed by a live Q&A session for analysts and investors.
- A link to the Investor Webinar will be available in the Events & Presentations section of the Company’s Investor Relations website at https://ir.bruker.com .
Technology,
Research,
Genetics,
Nanotechnology,
Biotechnology,
Health,
Pharmaceutical,
Other Science,
Science,
Corporation,
UPC,
BRKR,
NanoString Technologies,
RNA,
Federal Patent Court (Germany),
SMI,
Patent,
Court,
Acquisition,
Genomics,
Federal Patent Court Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No.
Key Points:
- Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No.
- NanoString is now a Bruker business following Bruker’s asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024.
- The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString’s CosMx Spatial Molecular Imager (SMI) products for RNA detection.
- The Federal Patent Court ruled that the German part of the 928 Patent is invalid.
Research,
Science,
Goldman Sachs,
Corporation,
BRKR,
Uncertainty,
NanoString Technologies,
AlixPartners,
Willkie Farr & Gallagher,
Acquisition,
Morgan, Lewis & Bockius,
Growth Bruker Corporation (Nasdaq: BRKR) today announced that it has closed its asset acquisition of the business of NanoString Technologies, Inc. , headquartered in Seattle, Washington, a leading provider of life-science research solutions for spatial transcriptomics and gene expression analysis.
Key Points:
- Bruker Corporation (Nasdaq: BRKR) today announced that it has closed its asset acquisition of the business of NanoString Technologies, Inc. , headquartered in Seattle, Washington, a leading provider of life-science research solutions for spatial transcriptomics and gene expression analysis.
- Under the asset purchase agreement, Bruker has now acquired substantially all of the assets and rights associated with NanoString’s business, including the nCounter®, GeoMx®, CosMx™ and AtoMx™ product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities.
- Due to significant business disruption and uncertainty, Bruker is not yet in a position to give financial guidance on the NanoString business for 2024, but Bruker expects to add this business to Bruker’s guidance by 2025 and beyond.
- NanoString is represented by Willkie Farr & Gallagher LLP as counsel, AlixPartners LLP as restructuring advisor and Perella Weinberg Partners L.P. as restructuring investment banker.
Other Health,
Research,
Technology,
Infectious Diseases,
Hospitals,
Artificial Intelligence,
Semiconductor,
Genetics,
Science,
Biotechnology,
Other Science,
Health,
MALDI,
Corporation,
MDX,
FY,
History,
Viral,
Microbiology,
Acquisition,
EPS,
Infection,
IVD,
Pharmaceutical industry Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business.
Key Points:
- Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business.
- “We are very pleased to welcome ELITech to Bruker,” said Frank H. Laukien, Bruker’s President and CEO.
- “The ELITech molecular diagnostics sample-to-answer platforms for viral infection and other esoteric MDx assays complement our MALDI Biotyper® platform for bacterial and fungal identification.
- The ELITech team is very much looking forward to becoming part of the Bruker family.”
Going forward, ELITech will become the Bruker Molecular Diagnostics business within the Bruker Microbiology & Infection Diagnostics division of the Bruker CALID Group.
